XML 73 R44.htm IDEA: XBRL DOCUMENT v3.24.1

Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Expense Recognized for Employee Services Received

During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses:

									Years ended December 31,
(in millions €)			Note									2023			2022			2021
Expense arising from equity-settled share-based payment arrangements												44.1			46.5			61.0
Employee Stock Ownership Plan			16.5									—			13.8			20.2
Chief Executive Officer Grant			16.4									1.2			3.1			5.9
Management Board Grant(1)			16.3									3.2			4.3			2.4
BioNTech 2020 Employee Equity Plan for Employees Based Outside North America			16.1									36.3			25.3			32.5
InstaDeep Employee Incentive Plan(2)												3.4			—			—
Expense / (Income) arising from cash-settled share-based payment arrangements												7.3			61.5			32.7
Employee Stock Ownership Plan			16.5									(0.9)			53.4			6.3
Management Board Grant(1)			16.2, 16.3									(2.4)			—			3.6
BioNTech Restricted Stock Unit Plan for North America Employees			16.1									10.6			8.1			22.8
Total												51.4			108.0			93.7
Cost of sales												6.5			3.0			7.0
Research and development expenses												33.4			84.6			60.5
Sales and marketing expenses												1.0			0.8			0.5
General and administrative expenses												10.5			19.6			25.7
Total												51.4			108.0			93.7

(1)    In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of €1.1 million and €3.3 million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2).

(2)    As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of £15.0 million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments.

Employee Equity Plan

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Number and Share Price of Restricted Stock Units

Reconciliation of Outstanding Share-Options

						LTI-plus program			LTI 2020 program			LTI 2021 program			LTI 2022 program
As of January 1, 2022						372,011			242,416			110,036			—
Forfeited / Modified						(7,932)			(7,111)			(5,428)			—
Granted / Allocated						—			—			—			396,110
Settled(1)						(364,079)			—			—			—
As of December 31, 2022						—			235,305			104,608			396,110
As of January 1, 2023						—			235,305			104,608			396,110
Forfeited / Modified						—			(4,400)			(3,497)			(16,141)
As of December 31, 2023						—			230,905			101,111			379,969
thereof vested						—			175,523			51,905			96,466
thereof unvested						—			55,382			49,206			283,503

(1)    The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was €171.40.

Summary of Inputs Used in Measurement of Fair Value at Grant Date

						LTI-plus program			LTI 2020 program			LTI 2021 program			LTI 2022 program
Weighted average fair value						87.60			92.21			203.22			165.03
Waiting period (in years)						2.0			4.0			4.0			4.0

Management Board Grant

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:

						Allocation date February 2020			Allocation date May 12, 2021(1)			Allocation date May 17, 2021(1)			Allocation date May 2022(1)
Weighted average fair value						€10.83			€29.05			€27.64			€38.88
Weighted average share price						€28.20			€168.44			€179.46			€147.84
Exercise price(2)						€28.32			€167.63			€169.08			€137.65
Expected volatility						36.6		%	49.7		%	49.7		%	49.7		%
Expected life (years)						4.8			4.6			4.6			5.8
Risk-free interest rate						1.6		%	3.9		%	3.9		%	3.9		%

(1)    Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.

(2)    The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap. 

			Allocation date May 2023			Estimated allocation date 2024			Estimated allocation date 2025			Estimated allocation date 2026
Weighted average fair value(1)			€46.29			€43.67			€39.97			€32.86
Weighted average share price(1)			€98.93			€95.51			€95.51			€95.51
Exercise price(1)			€105.42			€96.82			€99.74			€105.13
Expected volatility			47.2		%	47.7		%	43.0		%	36.8		%
Expected life (years)(1)			5.8			5.8			5.8			5.8
Risk-free interest rate			3.7		%	3.9		%	3.9		%	3.9		%

(1)    Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.

Summary of Number and Weighted-Average Exercise Price of Share Options

The (phantom) share options allocated and expected to be allocated to our Management Board as of December 31, 2023, are presented in the table below.

						Allocation date February 2020			Allocation date May 12, 2021(1)			Allocation date May 17, 2021(1)			Allocation date May 2022(1)
(Phantom) share options outstanding						248,096			45,279			6,463			86,118
thereof allocated and vested but subject to performance and waiting requirements						186,072			22,640			3,232			21,531
thereof allocated and unvested						62,024			22,639			3,231			64,587
Weighted average exercise price (€)						28.32			167.63			169.08			137.65

(1)    Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.

						Allocation date May 2023(1)			Estimated allocation date 2024(1)			Estimated allocation date 2025(1)			Estimated allocation date 2026(1)
Share options outstanding / expected to be allocated						130,586			164,148			118,312			93,561
thereof allocated and unvested						130,586			—			—			—
Weighted average exercise price (€)						105.42			96.82			99.74			105.13

(1)    Valuation parameter derived from the Monte-Carlo simulation model.

Chief Executive Officer Grant

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:

						Grant date October 9, 2019
Weighted average fair value						€5.63
Weighted average share price						€13.60
Exercise price						€13.60
Expected volatility						41.4		%
Expected life (years)						5.4
Risk-free interest rate						1.5		%

Employee Stock Ownership Plan

Disclosure of terms and conditions of share-based payment arrangement [line items]

Summary of Inputs Used in Measurement of Fair Value at Grant Date

The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:

						Grant date November 15, 2018			Grant dates between February 21 and April 3, 2019			Grant dates between April 29 and May 31, 2019			Grant date December 1, 2019
Weighted average fair value						€7.41			€6.93			€7.04			€9.49
Weighted average share price						€14.40			€15.72			€16.03			€19.84
Exercise price(1)						€10.14			€15.03			€15.39			€15.82
Expected volatility						46.0		%	46.0		%	46.0		%	46.0		%
Expected life (years)						5.8			6.0			6.0			5.5
Risk-free interest rate						0.1		%	0.1		%	0.1		%	0.1		%

(1)    With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.

Summary of Number and Weighted-Average Exercise Price of Share Options

Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated:

						Share options outstanding			Number of ordinary shares underlying options			Weighted average exercise price (€)(1)
As of January 1, 2022						642,007			11,556,124			10.23
Modified(2)						(1,040)			(18,720)			10.14
Exercised(3)						(583,383)			(10,500,890)			10.14
As of December 31, 2022						57,584			1,036,514			11.10
As of January 1, 2023						57,584			1,036,514			11.10
Exercised(3)						(39,785)			(716,121)			11.04
As of December 31, 2023						17,799			320,393			11.24
thereof vested						17,799			320,393			11.24
thereof unvested						—			—			—

(1)    With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.

(2)    Rights have been modified to cash-settled rights, all other terms remained unchanged.

(3)    The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was €96.49 and €160.44 for all settlements during the years ended December 31, 2023 and 2022, respectively.

X

- Definition

The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2023-01-01
-Paragraph 47
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 2
-IssueDate 2023-01-01
-Paragraph 45
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2023-01-01
-Paragraph 45
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2023-01-01
-Paragraph 50
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: